Omalizumab as a Therapeutic Option for Nasal Polyposis in Moderate-to-Severe Persistent Allergic Asthma: Evidence From a Prospective Study in a Real-World Setting.

Ruiz-Hornillos, J; Rodríguez Jiménez, B; Feliu Vila, A; Moreno Fernández, A; Hernández García, M J; Domínguez-Ortega, J; on behalf the ESPLORA group

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57586

Title:	Omalizumab as a Therapeutic Option for Nasal Polyposis in Moderate-to-Severe Persistent Allergic Asthma: Evidence From a Prospective Study in a Real-World Setting.
Authors:	Ruiz-Hornillos, J Rodríguez Jiménez, B Feliu Vila, A Moreno Fernández, A Hernández García, M J Domínguez-Ortega, J on behalf the ESPLORA group View more
Keywords:	Moderate-to-severe persistent allergic asthma Nasal polyposis Omalizumab Prospective study Real-world View more
Mesh:	Anti-Asthmatic Agents Asthma Clinical Decision-Making Disease Management Humans Nasal Polyps Omalizumab Severity of Illness Index Treatment Outcome View more
Issue Date:	3-Jun-2020
Citation:	J Investig Allergol Clin Immunol.2020;(30)6:470-472
PMID:	32490823
URI:	https://hdl.handle.net/20.500.12530/57586
ISSN:	1018-9068
Appears in Collections:	Hospitales > H. U. Tajo > Artículos

Files in This Item:

The file with the full text of this item is not available due to copyright restrictions or because there is no digital version. Authors can contact the head of the repository of their center to incorporate the corresponding file.

Show full item record